Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ascentage Pharma Group International ( (HK:6855) ) has shared an announcement.
Ascentage Pharma has received clearance from the FDA and EMA to conduct a global Phase III trial of Lisaftoclax, a Bcl-2 inhibitor, in combination with azacitidine for treating higher-risk myelodysplastic syndrome (HR-MDS). This trial, known as GLORA-4, is significant as it is the only registrational Phase III study of a Bcl-2 inhibitor for HR-MDS globally, potentially addressing a major treatment gap and offering a new therapeutic option for patients with this challenging condition.
The most recent analyst rating on (HK:6855) stock is a Buy with a HK$40.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing novel therapies for cancer, hepatitis B, and age-related diseases. The company specializes in creating small molecule therapeutics that target key pathways in cancer biology, with a particular emphasis on apoptosis, or programmed cell death, to treat malignancies.
Average Trading Volume: 5,628,945
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.76B
See more data about 6855 stock on TipRanks’ Stock Analysis page.